FORM 53-901F

SECURITIES ACT

MATERIAL CHANGE REPORT UNDER
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

Item 1.	REPORTING ISSUER
	Cardiome Pharma Corp.
	6190 Agronomy Road, 6th Floor
	Vancouver, BC V6T 1Z3
Item 2.	DATE OF MATERIAL CHANGE
	September 28, 2004
Item 3.	PRESS RELEASE
	September 28, 2004 - Vancouver, British Columbia
Item 4.	SUMMARY OF MATERIAL CHANGE
	Cardiome Pharma Corp announced that it has exercised its right to place US$4 million of equity at C$7.89 with Fujisawa Healthcare, Inc. The equity was placed at a 25% premium to the 30 calendar day average market price of $6.31.
Item 5.	FULL DESCRIPTION OF MATERIAL CHANGE
	Cardiome Pharma Corp announced that it has exercised its right to place US$4 million of equity at C$7.89 with Fujisawa Healthcare, Inc. (“Fujisawa”). The equity was placed at a 25% premium to the 30 calendar day average market price of $6.31.
	The equity placement right is defined in the October 2003 co-development agreement in which Cardiome licensed North American rights to the intravenous formulation of RSD1235 to Fujisawa Healthcare Inc. Cardiome retains worldwide rights to oral RSD1235 for the prevention of AF and all rights to the intravenous formulations outside of Canada, US and Mexico. Cardiome stands to receive an additional US$54 million in milestones from Fujisawa over the course of the agreement, based upon the achievement of certain clinical and commercial milestones.
Item 6.	RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS
	Not Applicable.
Item 7.	OMITTED INFORMATION
	Not Applicable.

Item 8.	SENIOR OFFICER
	Name:                                                        Christina Yip
	Title:                                                          Vice President, Finance and Administration
	Phone No.:                                                604-677-6905

Item 9.	STATEMENT OF SENIOR OFFICER
	The foregoing accurately discloses the material change referred to herein.

Dated at Vancouver, British Columbia, this 28th day of September, 2004.

CARDIOME PHARMA CORP.
Per:
	Christina Yip, Vice President, Finance and Administration

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.